Company intelligence / Profile preview
Roca Therapeutics
Nice, Provence-Alpes-Côte d'Azur, Franceroca-therapeutics.org ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Roca Therapeutics is developing first-in-class, non-invasive small molecule therapies for severe ocular diseases. Their lead candidate, RCT001, targets metastatic uveal melanoma and aims to address disease mechanisms involving resistant angiogenesis and immunosuppressive inflammation. A second candidate is being developed for neovascular glaucoma associated with uveal melanoma. The company has completed a seed funding round to advance its programs toward IND/CTA readiness
- Therapeutic areas
- OncologyOphthalmology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Landmark BioVentures AG (co-founder/investor)SATT Sud-Est (investor)University Côte d’Azur/EUROBIOMED/Canceropole PACA [as investors/collaborators]
Beyond the preview
Go deeper on Roca Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Roca Therapeutics.